GAIN THERAPEUTICS
Gain Therapeutics is a developer of pharmacological chaperones drugs designed to treat rare metabolic disorders. The company's drugs utilize Minoryx Direct Enzyme Therapy to identify a new generation of uncomplicated adjuvants, enabling clients to help patients stabilize misfolding mutations and restore protein's enzymatic activity. It targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Established in 2017 and is headquartered in Bethesda, MD, USA.
GAIN THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Bethesda, Maryland, United States
Country:
United States
Website Url:
http://www.gaintherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
301-500-1556
Email Addresses:
[email protected]
Total Funding:
14.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Horizon 2020
Horizon 2020 investment in Grant - Gain Therapeutics
Eurostars
Eurostars investment in Grant - Gain Therapeutics
InnoSuisse
InnoSuisse investment in Grant - Gain Therapeutics
VitaTech S.A
VitaTech S.A investment in Series A - Gain Therapeutics
3B Future Health Fund
3B Future Health Fund investment in Series A - Gain Therapeutics
TiVentures
TiVentures investment in Series A - Gain Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-19 | Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer |
Official Site Inspections
http://www.gaintherapeutics.com Semrush global rank: 3.75 M Semrush visits lastest month: 3.6 K
- Host name: 104.16.150.108
- IP address: 104.16.150.108
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Gain Therapeutics"
About Us: Our Mission & Values | Gain Therapeutics
Dr. Terenzio Ignoni, joined Gain Therapeutic in June 2021 as SVP Quality and CMC bringing with him more than 22 years of hands-on experience in pharmaceutical technical operations, …See details»
Gain Therapeutics - Crunchbase Company Profile
Gain Therapeutics is a developer of pharmacological chaperones drugs designed to treat rare metabolic disorders. The company's drugs utilize Minoryx Direct …See details»
Gain Therapeutics - LinkedIn
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders And Provides Operational Update "We hope 2025 is a year of immense progress – not only for Gain but the field as a whole – and ...See details»
Gain Therapeutics - businessabc.net
Feb 25, 2025 Gain Therapeutics was founded in 2020 by a team of renowned scientists, physicians and entrepreneurs with a vision to redefine the landscape of therapeutic development.See details»
Gain Therapeutics | Investor Info, News & Corporate Updates
Mar 17, 2025 Stay updated on Gain Therapeutics’ stock info, events, press releases, and corporate updates. Explore key investor resources and company developments.See details»
Gain Therapeutics - Overview, News & Similar companies
May 22, 2024 Gain Therapeutics contact info: Phone number: (301) 500-1556 Website: www.gaintherapeutics.com What does Gain Therapeutics do? Gain Therapeutics, Inc. is …See details»
Gain Therapeutics - Craft
Oct 29, 2024 Gain Therapeutics has 3 employees across 3 locations and $55.18 k in annual revenue in FY 2023. See insights on Gain Therapeutics including office locations, competitors, …See details»
Gain Therapeutics Company Overview, Contact Details
Nov 24, 2023 Gain Therapeutics, Inc. hired Gene Mack as interim CEO on Jan 6th '25. BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) - Gain Therapeutics, Inc. (Nasdaq: …See details»
Behind the scenes of Gain Therapeutics COO: Matthias Alder
I want to positively influence the organization and work with my colleagues to achieve the company mission, which is to accelerate drug discovery and development with our platform …See details»
GT Gain Therapeutics SA – Swiss Biotech
A clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is …See details»
Gain Therapeutics, Inc. (Gain Therapeutics, Inc.) - 药物管线_专利_ …
Investor Contacts:Apaar Jammu and Chuck [email protected]@lifesciadvisors.com Media Contacts:Russo …See details»
News & Events | Gain Therapeutics Investor Relations
Mar 14, 2025 Get the latest updates, events, and announcements from Gain Therapeutics. Stay informed on key developments and corporate milestones for investors and stakeholders.See details»
Gain Therapeutics | LinkedIn
Gain Therapeutics | 4.558 Follower:innen auf LinkedIn. Unfolding the next generation of allosteric small molecule therapies to meet patient needs | Gain Therapeutics, Inc. is a clinical-stage …See details»
Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI …
Gain Therapeutics Revolutionary Drug Discovery: Combining Physics, Biochemistry, and Supercomputing; Oppenheimer Virtual Fireside Chat: Targeting the Undruggable – Latest …See details»
Gain Therapeutics’ collaboration with Zentalis Pharmaceuticals so ...
On April 20th, 2021, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology targets.See details»
Gain Therapeutics Reports Financial Results for the Fourth Quarter …
9 hours ago Cash, cash equivalent and marketable securities were $10.4 million as of December 31, 2024, compared to $16.8 million as of December 31, 2023.. About GT-02287 Gain …See details»
Gain Therapeutics Reports Financial Results for the Fourth Quarter …
First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025. BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: …See details»
Gain Therapeutics Reports Financial Results for the Fourth
10 hours ago Gain Therapeutics, Inc Consolidated Statements of Operations Year Ended December 31, 2024 2023 Revenues: Collaboration revenuesSee details»
Gain Therapeutics Revolutionary Drug Discovery
Discovering treatments for patients that currently have no available disease-modifying options is the priority of Gain Therapeutics. Specifically, there is a large unmet need for patients suffering …See details»
Gain Therapeutics Reports Financial Results for the Fourth Quarter …
9 hours ago First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. …See details»